Celgene Co. (CELG) Stake Decreased by Valeo Financial Advisors LLC

Valeo Financial Advisors LLC decreased its holdings in Celgene Co. (NASDAQ:CELG) by 82.1% in the first quarter, HoldingsChannel.com reports. The fund owned 351 shares of the biopharmaceutical company’s stock after selling 1,608 shares during the quarter. Valeo Financial Advisors LLC’s holdings in Celgene were worth $33,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp boosted its stake in Celgene by 36.9% during the fourth quarter. BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp now owns 342,301 shares of the biopharmaceutical company’s stock valued at $21,938,000 after buying an additional 92,209 shares during the last quarter. Tibra Equities Europe Ltd bought a new position in Celgene during the first quarter valued at approximately $6,396,000. Bell Asset Management Ltd boosted its stake in Celgene by 13.7% during the fourth quarter. Bell Asset Management Ltd now owns 78,822 shares of the biopharmaceutical company’s stock valued at $5,052,000 after buying an additional 9,525 shares during the last quarter. Morgan Stanley boosted its stake in Celgene by 20.4% during the third quarter. Morgan Stanley now owns 3,236,323 shares of the biopharmaceutical company’s stock valued at $289,620,000 after buying an additional 549,404 shares during the last quarter. Finally, Global Trust Asset Management LLC boosted its stake in Celgene by 212.3% during the first quarter. Global Trust Asset Management LLC now owns 4,557 shares of the biopharmaceutical company’s stock valued at $430,000 after buying an additional 3,098 shares during the last quarter. 74.81% of the stock is owned by hedge funds and other institutional investors.

Shares of CELG stock opened at $94.30 on Thursday. Celgene Co. has a 1 year low of $58.59 and a 1 year high of $95.44. The company has a current ratio of 2.23, a quick ratio of 2.12 and a debt-to-equity ratio of 3.21. The company has a market cap of $66.24 billion, a price-to-earnings ratio of 12.39, a P/E/G ratio of 0.43 and a beta of 1.71.

Celgene (NASDAQ:CELG) last issued its quarterly earnings data on Thursday, January 31st. The biopharmaceutical company reported $2.39 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.32 by $0.07. Celgene had a return on equity of 114.66% and a net margin of 26.48%. The business had revenue of $4.04 billion for the quarter, compared to the consensus estimate of $3.98 billion. During the same period in the prior year, the business posted $2.00 earnings per share. On average, equities research analysts anticipate that Celgene Co. will post 10.01 earnings per share for the current fiscal year.

In other Celgene news, Director Ernest Mario purchased 2,000 shares of Celgene stock in a transaction dated Tuesday, February 12th. The shares were purchased at an average cost of $89.99 per share, for a total transaction of $179,980.00. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director James J. Loughlin sold 23,466 shares of the stock in a transaction that occurred on Thursday, February 7th. The stock was sold at an average price of $87.29, for a total value of $2,048,347.14. Following the completion of the sale, the director now owns 62,102 shares in the company, valued at $5,420,883.58. The disclosure for this sale can be found here. Corporate insiders own 0.39% of the company’s stock.

CELG has been the subject of a number of research reports. Leerink Swann lowered Celgene from an “outperform” rating to a “market perform” rating in a research note on Thursday, January 3rd. BidaskClub raised Celgene from a “strong sell” rating to a “sell” rating in a research note on Friday, January 4th. Robert W. Baird raised Celgene from a “neutral” rating to an “outperform” rating and set a $92.00 price target for the company in a research note on Friday, January 4th. Zacks Investment Research raised Celgene from a “hold” rating to a “strong-buy” rating and set a $99.00 price target for the company in a research note on Wednesday, January 23rd. Finally, Canaccord Genuity lowered Celgene from a “buy” rating to a “hold” rating in a research note on Thursday, January 3rd. One investment analyst has rated the stock with a sell rating, eighteen have issued a hold rating and nine have assigned a buy rating to the company’s stock. Celgene has an average rating of “Hold” and an average target price of $99.41.

TRADEMARK VIOLATION WARNING: This article was originally reported by Community Financial News and is the property of of Community Financial News. If you are viewing this article on another website, it was stolen and republished in violation of U.S. & international trademark and copyright laws. The correct version of this article can be accessed at https://www.com-unik.info/2019/04/18/celgene-co-celg-stake-decreased-by-valeo-financial-advisors-llc.html.

Celgene Company Profile

Celgene Corporation, a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of cancer and inflammatory diseases worldwide. It offers REVLIMID, an oral immunomodulatory drug for multiple myeloma (MM), myelodysplastic syndromes (MDS), and mantle cell lymphoma; POMALYST/IMNOVID to treat multiple myeloma; OTEZLA, a small-molecule inhibitor of phosphodiesterase 4 for psoriatic arthritis and psoriasis; and ABRAXANE to treat breast, non-small cell lung, pancreatic, and gastric cancers.

Featured Story: What is Liquidity?

Want to see what other hedge funds are holding CELG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Celgene Co. (NASDAQ:CELG).

Institutional Ownership by Quarter for Celgene (NASDAQ:CELG)

Receive News & Ratings for Celgene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene and related companies with MarketBeat.com's FREE daily email newsletter.



Comments


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit